ArticlemAbs2026
Systematic characterization of lysine glucuronidation in a bispecific antibody.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents a systematic characterization of lysine glucuronidation that was revealed during the charge variant characterization of a bispecific antibody (bsAb). Site-specific quantitation by Glu-C/Asp-N peptide mapping suggested that glucuronidation occurred randomly across surface lysine residues. To understand the impact of glucuronidation on the structure and function of the bsAb, stressed samples with up to 84% total glucuronidation were generated and analyzed by a comprehensive panel of analytical methods. The results suggested that glucuronidation caused an acidic isoelectric point (pI) shift in the charge profile. However, it does not affect the higher-order structure or bioactivities of the bsAb, including antibody-dependent cell-mediated cytotoxicity, antigen binding, or Fc receptor interaction. To support routine process monitoring, a fit-for-purpose subunit mass method was developed and qualified for quantitation of glucuronidation, offering a higher-throughput alternative to peptide mapping for assessing process consistency and product comparability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.